RAD June 2024 Abstracts and Posters
728 Evaluation of risk factors for dupilumab-associated ocular sequelae in the treatment of atopic dermatitis
Varsha Reddy, Alexa Lum, Katerina Kitsios, Swarna Shil, Alanna Nattis
729 A phase 2b, randomized, double-blinded, parallel-group, placebo-controlled, international, multicenter, study to evaluate the efficacy and safety of rezpegaldesleukin in adults with moderate-to-severe atopic dermatitis
Melinda Gooderham, Charles Lynde, Maryam Shayesteh Alam, Neil Sadick, Craig A Rohan, William Philip Werschler, Adelaide A Hebert, Vivian T Laquer, Maxwell Sauder, James Q. Del Rosso, Timothy Rodgers, Ricardo Tan, Stephen Schleicher, Dedée F Murrell, Pablo Fernandez-Peñas, Adam Reich, Spyridon Gkalpakiotis, Juan Ruano Ruiz, Andreas Wollenberg, Jacek C Szepietowski, Michael Sticherling, Ansgar J. Weyergraf24, Suzana Ljubojević Hadžavdić, Wojciech Baran, Trinidad Montero Vilchez, Telegdy Eniko, Michael Sebastian, Sohail Chaudhry, Zachary Lee, Danni Yu, Yi Liu, Wang Waltz, Jenny Gilbert, Lucinda M. Elko-Simms, Christie Fanton, Charleen Jue, Mary Tagliaferri, Jonathan Zalevsky, David Rosmarin
730 Patient opinions on healthcare provider interactions and current treatment satisfaction in adults with atopic dermatitis by race and ethnicity
Candrice R. Heath, Vivian Y. Shi, Wendy Smith Begolka, Elizabeth D. Bacci, Melissa L. Constantine, Julia R. Correll, Amber Reck Atwater, Evangeline J. Pierce, Raj Chovatiya
731 Quality of life in atopic dermatitis: the patient perspective
Victoria Jiminez, Michaela Crawford, Tiffany Mayo
732 EASI 90 response sustained up to 38 weeks after lebrikizumab withdrawal despite negligible serum concentrations
Jonathan I. Silverberg, Thomas Bieber, Kilian Eyerich, April W. Armstrong, Brian J Nickoloff, Chitra R Natalie, Gaia Gallo, Angela Okragly, Chenjia Xu, Brian Moser, Maria Jose Rueda, Hany Elmaraghy, Ozge Uluckan, Johann E. Gudjonsson
733 Nemolizumab elicits fast itch response in atopic dermatitis within 2 days: a post hoc analysis of ARCADIA 1 and 2 data
Jonathan I Silverberg, Linda Stein-Gold, Diamant Thaçi, Andrew E Pink, Kim A Papp, Franz J Legat, Vivian T Laquer, Soo Yeon Cheong, Liliana Ulianov, Anna Ryzhkova, Christophe Piketty
734 Efficacy and safety of upadacitinib vs dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis: results of an open-label, efficacy assessor-blinded head-to-head phase 3b/4 study (Level Up)
Jonathan I. Silverberg, Christopher Bunick, H. Chih-ho Hong, Pedro Mendes-Bastos, Linda Stein Gold, Antonio Costanzo, Nadia Ibrahim, Cristina Sancho, Xiaoqiang Wu, Yu Han, Gweneth Levy, Kathy Altman, Kilian Eyerich
735 A Case Series of Dupilumab for Vitiligo and Alopecia Areata in the Setting of AD
Dev Patel, Ben Hu, Omar Alani, and Nanette Silverberg MD